Leftagraph

Every financial statement,
one clean chart.

Search any US-listed company. Data straight from SEC filings.

PROBuild your own list with the screener

4D Molecular Therapeutics, Inc. (FDMT) financial statements

Number look wrong? Tell us

Data table
PROBuild your own list with the screener

4D Molecular Therapeutics, Inc. (FDMT), most recent 12 months reported: revenue $92.01M, net loss $179.18M, free cash flow -$109.62M. Latest balance sheet on file: liquid cash $361.33M, total debt $19.59M, net cash $341.75M. From SEC filings. Others in Biological Products, (No Diagnostic Substances): Autolus Therapeutics plc · GINKGO BIOWORKS HOLDINGS, INC. · Century Therapeutics, Inc. · KYMERA THERAPEUTICS, INC. · Protalix BioTherapeutics, Inc. · COMPUGEN LTD · CHAMPIONS ONCOLOGY, INC. · FENNEC PHARMACEUTICALS INC.

Stock screener

Watchlist